Short answer
HAEMONETICS CORP (HAE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $358M (up 9.3% year over year) with net income of $46M.
Q3 2026 key financials · XBRL
- Revenue
- $358M
- +9.3% YoY · +5.4% QoQ
- Net income
- $46M
- +19.7% YoY · +40.3% QoQ
- Operating margin
- 21.0%
- Gross margin
- 61.7%
- EPS (diluted)
- $1.00
- +23.5% YoY · +38.9% QoQ
Source: XBRL data from the HAEMONETICS CORP (HAE) Q3 2026 10-Q on SEC EDGAR. USD.
HAEMONETICS CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $357.8M, up 9.3% YoY from $327.3M
- Operating margin 21.0% vs 17.9% YoY, net margin 12.9% vs 11.8%
- Best performer: Plasma revenue $162.6M, up 16.5%; worst: Interventional Technologies $60.5M, up 2.4%
- Cash $260.7M vs $245.4M; operating cash flow $180.4M vs $128.7M for six months
- $100.0M revolving-credit repayment; CSL rollout expected by end of calendar year 2027, timing subject to change
Risk Factors
- No material changes from the fiscal 2026 Form 10-K risk factors
- Carried-forward risks remain unchanged, with no new triggers identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HAEMONETICS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.